Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 7/20 | 0.51 |
| ▸ | BACE1 | P56817 | 7/20 | 0.51 |
| ▸ | BCHE | P06276 | 5/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | FABP6 | P51161 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991248 | 1.00 | GRIN2B (0.56) | GRIN2BMEN1KMT2ARAB9AACHE | |
| SCHEMBL2989349 | 1.00 | GRIN2B (0.56) | GRIN2BMEN1KMT2ARAB9AACHE | |
| Hydrochloric Acid SCHEMBL2992400 | 0.98 | MEN1 (0.58) | GRIN2BMEN1KMT2ARAB9AACHE | |
| Hydrochloric Acid SCHEMBL2992401 | 0.98 | MEN1 (0.58) | GRIN2BMEN1KMT2ARAB9AACHE | |
| SCHEMBL17335875 | 0.86 | GRIN2B (0.59) | GRIN2BMEN1KMT2ARAB9AACHE | |
| SCHEMBL17335932 | 0.86 | GRIN2B (0.59) | GRIN2BMEN1KMT2ARAB9AACHE | |
| SCHEMBL17335880 | 0.86 | GRIN2B (0.59) | GRIN2BMEN1KMT2ARAB9AACHE | |
| SCHEMBL25046233 | 0.84 | BCHE (0.49) | MEN1KMT2ARAB9AACHEBACE1 | |
| SCHEMBL663239 | 0.84 | GRIN2B (0.74) | GRIN2BMEN1KMT2ARAB9AACHE | |
| SCHEMBL25802864 | 0.82 | GRIN2B (0.62) | GRIN2BMEN1KMT2ARAB9AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278442-B2 | Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders | PROSIDION LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-8278442-B2 | Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders | PROSIDION LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| WO-2008142454-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | OPRM1, OPRK1, OPRD1 | GRIN2B 306/4885MEN1 4566/4885KMT2A 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.